Bristol Myers Earnings Are ‘a Tale of 2 Trends’ as Guidance Falls Short
The drugmaker Bristol Myers Squibb has been a standout among its big pharma peers over the past six months, scoring a ...
FiercePharma22h
Bristol Myers Squibb, amid restructuring, unveils plan to cut another $2B in costs
BMS is not the only U.S. pharma giant making massive cuts. Last year, Pfizer revealed a similar plan to reduce $1.5 billion ...
Bristol Myers, bracing for key patent losses, deepens cost-cutting plan
The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies across multiple areas of the business,” its CFO told analysts on a conference ...
devdiscourse14h
Health Sector Shake-Ups: From Bristol Myers' Forecasts to Global Aid Impacts
Recent health news includes Bristol Myers' projected revenue dip due to generic competition and cost cuts, Trump's tariffs ...
BioPharma Dive16h
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the ...
Bristol Myers Squibb Warns Near-Term Impact Due To Generics On 2025 Sales Forecast, Outlines $2 Billion In Additional Cost Cuts
Bristol Myers Squibb & Co (NYSE:BMY) posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 ...
These Stocks Are Moving the Most Today: Qualcomm, Lilly, Skyworks, Ford, Honeywell, Strategy, Roblox, Bristol Myers, Amazon, and More
Qualcomm trades lower after earnings, Eli Lilly stock rises on upbeat guidance, Skyworks says its share of the business to ...